SPRO · Spero Therapeutics, Inc.
$1.18
+0.02 (+1.72%)
At close · Jul 24
Market Cap
$68.90M
Shares
57.90M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$66.8M
+39.2%
FY2025
Net Income
$8.57M
+112.5%
FY2025
Operating Margin
9.45%
+162.4pp
FY2025
Diluted EPS
$0.15
+111.8%
FY2025
Operating Cash Flow
-$12.62M
+46.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $61.19M | $66.8M | $47.98M | $103.78M | $53.51M | $18.26M | $9.33M | $18.15M | $3.97M | — | |
| $27.77M | $38.47M | $96.76M | $51.44M | $47.59M | $64.53M | $67M | $65.78M | $33.89M | $32.87M | |
| $19.24M | $21.18M | $23.7M | $25.55M | $36.48M | $41.7M | $21.44M | $15.59M | $12.89M | $10.84M | |
| — | $0 | $2000 | $367K | $869K | $646K | $761K | $750K | $409K | $363K | |
| $83K | $258K | $877K | $0 | $11.63M | — | — | — | — | — | |
| $47.68M | $60.49M | $121.34M | $82.3M | $95.71M | $106.23M | $88.44M | $81.36M | $46.77M | $43.71M | |
| $13.51M | $6.31M | -$73.36M | $21.48M | -$42.2M | -$87.97M | -$79.11M | -$63.22M | -$42.81M | -$41.73M | |
| — | 9.45% | -152.91% | 20.7% | -78.86% | -481.87% | -847.94% | -348.36% | -1079.32% | — | |
| — | $6.31M | -$73.36M | $21.85M | -$41.33M | -$87.33M | -$78.35M | -$62.47M | -$42.4M | -$41.37M | |
| $1.98M | $2.51M | $4.74M | $3.94M | $1.11M | $346K | $401K | $1.33M | — | — | |
| $1.99M | $2.52M | $4.8M | $3.92M | -$4.22M | -$1.79M | $833K | $2.29M | $1.14M | $1.84M | |
| — | $8.83M | -$68.57M | $25.4M | -$46.42M | -$89.76M | -$78.28M | -$60.93M | -$41.66M | -$39.89M | |
| — | $261K | $0 | $2.6M | $0 | $0 | $0 | $0 | $0 | $0 | |
| $15.24M | $8.57M | -$68.57M | $22.81M | -$46.42M | -$89.8M | -$78.3M | -$60.9M | -$41.66M | -$38.74M | |
| — | 12.83% | -142.91% | 21.98% | -86.74% | -491.89% | -839.23% | -335.59% | -1050.48% | — | |
| — | — | — | — | — | — | — | — | -$1.14M | -$1.14M | |
| — | — | — | — | $46.42M | -$89.76M | -$78.83M | — | -$41.66M | -$46.1M | |
| — | — | — | $22.81M | -$46.41M | -$89.75M | -$78.3M | -$60.88M | -$41.69M | — | |
| USD/shares | — | $0.15 | -$1.27 | $0.43 | -$1.23 | — | — | — | — | — |
| USD/shares | — | $0.15 | -$1.27 | $0.43 | -$1.23 | — | — | — | — | — |
| shares | — | 56.02M | 54.04M | 52.7M | 37.59M | 30.9M | 22.39M | 18.16M | 16M | 2.59M |
| shares | — | 59.04M | 54.04M | 52.99M | 37.59M | 30.9M | 22.39M | 18.16M | 16M | 2.59M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
4.41×
Biotechnology median 7.07×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Collaboration Revenue Related Party | $47,033,000 | $27,025,000 | $95,802,000 |
| Collaboration Revenue | $12,586,000 | $371,000 | $933,000 |
| Grant Revenue | $7,183,000 | $20,581,000 | $7,046,000 |